199 related articles for article (PubMed ID: 28943357)
1. Divergent JNK Phosphorylation of HDAC3 in Triple-Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and Selectivity.
Hanigan TW; Aboukhatwa SM; Taha TY; Frasor J; Petukhov PA
Cell Chem Biol; 2017 Nov; 24(11):1356-1367.e8. PubMed ID: 28943357
[TBL] [Abstract][Full Text] [Related]
2. Mitotic Activation of a Novel Histone Deacetylase 3-Linker Histone H1.3 Protein Complex by Protein Kinase CK2.
Patil H; Wilks C; Gonzalez RW; Dhanireddy S; Conrad-Webb H; Bergel M
J Biol Chem; 2016 Feb; 291(7):3158-72. PubMed ID: 26663086
[TBL] [Abstract][Full Text] [Related]
3. The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors.
Cao F; Zwinderman MRH; Dekker FJ
Molecules; 2018 Mar; 23(3):. PubMed ID: 29498635
[TBL] [Abstract][Full Text] [Related]
4. Structure of 'linkerless' hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket.
Tabackman AA; Frankson R; Marsan ES; Perry K; Cole KE
J Struct Biol; 2016 Sep; 195(3):373-378. PubMed ID: 27374062
[TBL] [Abstract][Full Text] [Related]
5. The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
Choi SE; Pflum MK
Bioorg Med Chem Lett; 2012 Dec; 22(23):7084-6. PubMed ID: 23089527
[TBL] [Abstract][Full Text] [Related]
6. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
7. The Application of Non-Invasive Apoptosis Detection Sensor (NIADS) on Histone Deacetylation Inhibitor (HDACi)-Induced Breast Cancer Cell Death.
Hsu KW; Huang CY; Tam KW; Lin CY; Huang LC; Lin CL; Hsieh WS; Chi WM; Chang YJ; Wei PL; Chen ST; Lee CH
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393914
[TBL] [Abstract][Full Text] [Related]
8. Targeting breast cancer stem cells by novel HDAC3-selective inhibitors.
Hsieh HY; Chuang HC; Shen FH; Detroja K; Hsin LW; Chen CS
Eur J Med Chem; 2017 Nov; 140():42-51. PubMed ID: 28923385
[TBL] [Abstract][Full Text] [Related]
9. Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
Ho TCS; Chan AHY; Ganesan A
J Med Chem; 2020 Nov; 63(21):12460-12484. PubMed ID: 32608981
[TBL] [Abstract][Full Text] [Related]
10. Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs.
Xiao Y; Wang J; Zhao LY; Chen X; Zheng G; Zhang X; Liao D
Chem Commun (Camb); 2020 Aug; 56(68):9866-9869. PubMed ID: 32840532
[TBL] [Abstract][Full Text] [Related]
11. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly.
Rajendran P; Delage B; Dashwood WM; Yu TW; Wuth B; Williams DE; Ho E; Dashwood RH
Mol Cancer; 2011 May; 10():68. PubMed ID: 21624135
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors: a review on class-I specific inhibition.
Behera J; Jayaprakash V; Sinha BN
Mini Rev Med Chem; 2015; 15(9):731-50. PubMed ID: 25994050
[TBL] [Abstract][Full Text] [Related]
14. Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
Zhang K; Liu Z; Yao Y; Qiu Y; Li F; Chen D; Hamilton DJ; Li Z; Jiang S
J Med Chem; 2021 Apr; 64(7):4020-4033. PubMed ID: 33745280
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
[TBL] [Abstract][Full Text] [Related]
16. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
17. Scaffold dependent histone deacetylase (HDAC) inhibitor induced re-equilibration of the subcellular localization and post-translational modification state of class I HDACs.
Hanigan TW; Taha TY; Aboukhatwa SM; Frasor J; Petukhov PA
PLoS One; 2017; 12(10):e0186620. PubMed ID: 29045501
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells.
Wang ZT; Chen ZJ; Jiang GM; Wu YM; Liu T; Yi YM; Zeng J; Du J; Wang HS
Cell Signal; 2016 May; 28(5):506-515. PubMed ID: 26876786
[TBL] [Abstract][Full Text] [Related]
19. A cyclodextrin-capped histone deacetylase inhibitor.
Amin J; Puglisi A; Clarke J; Milton J; Wang M; Paranal RM; Bradner JE; Spencer J
Bioorg Med Chem Lett; 2013 Jun; 23(11):3346-8. PubMed ID: 23591111
[TBL] [Abstract][Full Text] [Related]
20. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
